Are we really ready for dual therapy in naive people with HIV? The experience from a large university hospital in Rome, Italy-Reference-Cited by-同舟云学术

Are we really ready for dual therapy in naive people with HIV? The experience from a large university hospital in Rome, Italy

Published:2023-12-29 Issue:2 Volume:79 Page:473-475
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Salvo Pierluigi Francesco¹^ORCID,Ciccullo Arturo²^ORCID,Iannone Valentina¹,Steiner Rebecca Jo¹,Lamanna Francesco¹,Passerotto Rosa Anna¹,Carbone Andrea¹,Borghetti Alberto³,Di Giambenedetto Simona¹⁴,Baldin Gianmaria¹⁴

Affiliation:

1. Dipartimento di Sicurezza e Bioetica—Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore , Rome , Italy

2. Infectious Diseases Unit, San Salvatore Hospital , L’Aquila , Italy

3. Department of Clinical and Experimental Medicine, University of Pisa , Pisa , Italy

4. Fondazione Policlinico Universitario ‘Agostino Gemelli’, IRCCS , Rome , Italy

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

https://academic.oup.com/jac/article-pdf/79/2/473/56418323/dkad405.pdf

Reference5 articles.

1. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA panel;Ghandi;JAMA,2023

2. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-2 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials;Cahn;J Acquir Immune Defic Syndr,2020

3. 48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: a multicenter real-life cohort;Cabello-Ubeda;PLoS One,2022

4. Efficacy and safety of dolutegravir plus lamivudine as a first-line regimen in clinical practice;Ciccullo;AIDS Res Hum Retroviruses,2021